Smith & Nephew SNATS, Inc. (SNN) To Go Ex-Dividend on October 2nd

Smith & Nephew SNATS, Inc. (NYSE:SNN) declared a dividend on Tuesday, August 4th. Shareholders of record on Friday, October 2nd will be paid a dividend of 0.312 per share by the medical equipment provider on Friday, November 6th. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Smith & Nephew SNATS has a payout ratio of 42.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Smith & Nephew SNATS to earn $2.48 per share next year, which means the company should continue to be able to cover its $0.93 annual dividend with an expected future payout ratio of 37.5%.

Smith & Nephew SNATS Trading Down 1.0%

Shares of SNN opened at $30.14 on Thursday. Smith & Nephew SNATS has a twelve month low of $28.56 and a twelve month high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The firm’s 50 day moving average price is $30.45 and its two-hundred day moving average price is $32.16.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Barclays cut shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday. Weiss Ratings cut Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. Sanford C. Bernstein set a $31.85 price target on Smith & Nephew SNATS in a research note on Monday, May 11th. Wall Street Zen upgraded Smith & Nephew SNATS from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 4th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Smith & Nephew SNATS in a research report on Monday, May 25th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.